Promius Pharma Initiates Phase III Clinical Trials of DFD-03 for The Treatment of Acne Vulgaris

PRINCETON, N.J., Nov. 9, 2017 /PRNewswire/ -- Promius Pharma, announced today the enrollment of subjects into the phase 3 clinical trials of DFD-03, a tazarotene formulation for the treatment of mild to moderate acne vulgaris.

"Promius Pharma's development of novel pipeline assets to treat conditions like acne vulgaris is encouraging," said Dr. Linda Stein Gold, Director of Dermatology Clinical Research at Henry Ford Health System in Detroit, MI. "Research is critical to providing patients with the treatment options of the future."

This short-contact formulation is expected to bring a new dimension to the treatment of acne patients.

About Promius Pharma LLC
Promius Pharma is a wholly owned subsidiary of Dr. Reddy's Laboratories, one of the largest and most respected pharmaceutical companies in the world. With a robust commercial infrastructure and extensive research and development capabilities through its parent company, Promius Pharma is committed to bringing new products to market that meet patients' needs in dermatology and neurology. For more information, visit www.promiuspharma.com.

Contact information:
Promius Pharma, LLC
107 College Rd E
Princeton, NJ 08540
www.promiuspharma.com

Media Relations:
Lori McCreary (USA)
lmccreary@drreddys.com
+1 (609) 375-2995

Copyright 2017 Promius Pharma, LLC

Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management's current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates , interest rates , persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganisation , including related integration issues. The company assumes no obligation to update any information contained herein.

View original content:http://www.prnewswire.com/news-releases/promius-pharma-initiates-phase-3-clinical-trials-of-dfd-03-for-the-treatment-of-acne-vulgaris-300552470.html

SOURCE Promius Pharma LLC